Pathological fractures are a common complication of plasma cell dyscrasias (PCD) and are associated with significant morbidity. Routine use of bisphosphonates over the past decade has aimed to reduce the risk of fractures in patients with multiple myeloma, but despite this, fractures continue to represent a significant burden of disease. In this study we report the fracture rate of hospital in-patients with PCD in England. Data from the national registry Hospital Episode Statistics between 2001 and 2015 were used to determine fracture rate and its effect on overall survival. Fracture rates were 17Á8 times higher than the general population in the first year after admission with PCD, and remained elevated for up to 10 years after first admission. The increased fracture risk preceded the first admission with PCD and, conversely, the incidence of PCD increased after admission with one or more fractures. Overall survival is improving with PCD, however poorer survival is found in patients with a preceding fracture (Hazard ratio 1Á20). Despite widespread bisphosphonate use, fractures remain common in PCD, and are associated with poorer outcomes.
Multiple myeloma (MM) is commonly associated with the destruction of bone. Over the course of the disease an estimated 81% of patients will develop a fracture (Melton et al, 2005) , most commonly at diagnosis, with up to a third of patients presenting with a fracture (Melton et al, 2005) . Fractures in MM are associated with increased mortality and morbidity due to immobility, reduced function and bone pain in 58% of patients (Kyle et al, 2003) .
Monoclonal gammopathy of undetermined significance (MGUS) almost always precedes MM for at least 2 years (Landgren et al, 2009; Weiss et al, 2009) , and is itself associated with an increased risk of fractures (Melton et al, 2004; Gregersen et al, 2006; Kristinsson et al, 2010) . However, the risk of fracture is not correlated with M-protein concentration (Melton et al, 2004) , and does not predict progression to MM (Kristinsson et al, 2010) . Reducing the risk of fractures is one of the key aims of supportive treatment in MM (Terpos et al, 2009) . Bisphosphonates reduce bone pain and the risk of fractures (Berenson et al, 1996) and are used routinely as supportive therapy in MM. Meta-analysis has found that bisphosphonate use can reduce the risk of vertebral fracture by 26%, but the residual risk of fracture remains high (Mhaskar et al, 2012) . Patients who present to hospital with a fracture are not routinely screened for an underlying plasma cell clone and therefore the true incidence of fractures associated with MGUS or MM is unknown.
Hospital Episode Statistics (HES; http://content.digital.nhs. uk/hes) is a large data repository containing details about all National Health Service (NHS) hospital inpatient admissions in England. This dataset has been validated in a research context (Thorn et al, 2016) , and has been used to describe the epidemiology and outcomes of patients with well defined conditions who are admitted to hospital. HES has been used to assess the incidence of haematological malignancies across different ethnicities (Shirley et al, 2013) and has provided an insight into survival in patients with MM with acute kidney injury (Evison et al, 2016) .
The risk of fracture in MM and related plasma cell dyscrasias (PCD) represents a significant source of morbidity, and elevated fracture rates have been described separately in MM and MGUS (Melton et al, 2005; Gregersen et al, 2006) . In this study, we use HES data to quantify the burden of research paper fractures resulting in hospital admission in patients with PCD at both the time of diagnosis and in the following decade, and assess the relationship between fracture incidence and overall survival.
Methods

Data acquisition
HES data were used to identify all adult inpatient hospital admissions in England between July 2001 and June 2015. International Classification of Diseases version 10 (ICD-10) codes were used to identify diagnoses. Multiple myeloma (C90Á0), plasma cell leukaemia (C90Á1) and plasmacytoma (C90Á2, C90Á3) were combined as PCD. The date that PCD first appeared on a patient's HES record, the PCD admission, was used as a proxy for the date of PCD diagnosis. Fractures were identified from both chapters XIII (diseases of the musculoskeletal system and connective tissue) and XIX (injury, poisoning and certain other consequences of external causes) of the ICD-10 (World Health Organisation, 2016) . Repeated counting of the same fracture was mitigated by excluding readmissions with a fracture code within 28 days. Information on patient survival was derived by linking to data from the Office of National Statistics (https://www.ons.gov.uk/). This study was registered as an audit, but did not require institutional review board approval as all data was pseudo-anonymised prior to retrieval. Patient-identifiable codes were not used, and small numbers were suppressed to prevent inadvertent patient identification, in accordance with national information governance standards.
Calculation of relative fracture and PCD rates
The direct method was used to age-and sex-standardise the overall fracture and PCD rates, using the English adult population from the 2011 census as the reference population. Relative fracture and PCD rates are expressed as the ratio of incidence in the population of interest compared with the general population.
Statistics
Overall survival was analysed using Cox proportional hazards modelling, incorporating age, sex, year of PCD admission and number of prior fractures as covariates, and post-PCD fracture as a time-dependent covariate. Competing risks analysis was used to measure fracture-free survival (time to first fracture, with death recorded as a competing risk), after adjusting for age, sex, year of PCD admission, and number of prior fractures. Statistical analyses were carried out using Stata SE 14 (StataCorp LP; College Station, TX, USA). Due to the large numbers of patients included in analyses, confidence intervals are narrow and results have very high statistical significance. However, this does not reflect the intrinsic sources of error and uncertainty within the data. Statistical significance levels are therefore misleading, and are not reported. The inappropriate reliance on P-values to demonstrate conclusive findings has been well-described (Ioannidis, 2005) .
Results
Study population
Between July 2001 and June 2015, a total of 66 079 patients were admitted with a diagnosis of PCD. Of these, 63 597 patients had a coded diagnosis of MM, 6895 with plasmacytoma and 1187 with plasma cell leukaemia. A substantial number (5273) of patients had more than one PCD diagnosis recorded during the study period. The earliest recorded diagnosis was used in all analyses. There were 3 813 468 fracture admissions identified during the study period in the general population, and 27 147 admissions with a fracture were recorded in patients with PCD.
Relative fracture rate after PCD admission
In the first year after PCD admission, the relative fracture rate was 17Á8 times that of the general population, and it remained over 6Á3 times higher up to 10 years later. In the year preceding PCD admission, the relative fracture rate was 4Á5 times higher than the general population. The inpatient fracture rate is seen to rise 2 years before PCD admission (Fig 1) .
Relative rate of PCD after admission with fractures
The number of admissions with a fracture over a five-year period was calculated for all patients, along with the subsequent incidence of PCD. Patients with a PCD admission before their first fracture were excluded. In the year after their most recent fracture, the rate of new PCD admissions was 63 per 100 000, a rate 5Á6 times higher than the general population. In patients with two or more fractures within 5 years, the relative rate of PCD was higher still (128 per 100 000, 11Á3 times that of the general population) in the year after the most recent fracture.
The relative PCD rate in the second year after an isolated fracture was 1Á7 times that of the general population. In patients with more than one fracture within 5 years, the relative rate was 2Á1. Relatively few patients were identified as developing PCD more than 3 years after a fracture, with a rate similar to the general population.
History of fracture affects risk of future fracture
Fracture-free survival after PCD admission was investigated; death was recorded as a competing risk (Table I ). The number of fractures in the 5 years prior to PCD admission was included, therefore PCD admissions before 2006 were excluded from this analysis. Age was not associated with the risk of fracture, and fractures were more likely in female patients. During the study period, the risk of fracture admissions remained constant. New fracture after PCD admission was strongly associated with a prior history of fracture, and the number of fractures in the 5 years prior to diagnosis of PCD had a significant impact on the subsequent risk of further fractures. Patients with one preceding fracture had a Hazard ratio (HR) of 1Á67 compared with those without a prior fracture, and in patients with multiple preceding fractures the HR was 2Á18.
History of fracture affects overall survival
Overall survival was analysed, taking into account the number of fractures suffered in the 5 years preceding PCD admission (Table II) . The effect of a fracture after PCD admission was included in the analysis, as a time-dependent covariate.
Overall survival was better in female patients, whereas survival decreased with advancing age. Over the course of the study period, overall survival improved by 5% each year. Compared with patients without a fracture (median survival 33 months, interquartile range [IQR] 8-89 months), patients who suffered one fracture in the 5 years before PCD admission had a poorer overall survival (median 21 months, IQR 4-62 months). Survival was worse (median 17 months, IQR 4-48 months) in patients who sustained more than one fracture during that period (unadjusted effect of fractures shown in Fig 2) . Survival was significantly poorer for patients with PCD after they sustained a new fracture (HR 2Á07).
Discussion
Using population-level data, this study has shown that the risk of fracture is highest around the time of first admission with a PCD. This risk then subsides, but remains significantly higher than the general population. This study found that, perhaps surprisingly, the risk of fracture has not improved over the last 14 years, which may be related to the improved overall survival for patients with myeloma. Suffering a new fracture with PCD is an indicator of a poorer prognosis. Whilst the routine use of bisphosphonates protects against skeletal related events (Mhaskar et al, 2012), they do not reverse skeletal damage. Fractures remain a common ongoing source of morbidity and mortality for patients with PCD and an important focus for future research, both for individual patients and for the health service as a whole. Over the study period, the overall survival of patients with PCD improved. This confirms NHS trends seen in England and Wales (National Institute for Health and Care Excellence 2016), and has occurred during a period that has seen the introduction of immuno-modulatory drugs and proteasome inhibitors. Despite this a new fracture in a patient with PCD is associated with worse overall survival, linking this common morbidity with mortality. This study also found that overall survival is poorer in patients with prior admissions with fractures, with the greatest risk in patients with more than one fracture in the preceding five years. Although it has been shown that fractures in MGUS do not predict progression to MM (Kristinsson et al, 2010) , the reason for the poorer survival could have a number of possible explanations. Patients with fractures may represent a population with increased frailty and comorbidities, and they may represent patients who have had a delay in diagnosis. Fractures may occur as a result of osteoporosis, which is also known to be more common in patients with MGUS (Drake, 2014) and could indicate a more biologically adverse disease.
The relative rate of fracture compared with the general population was seen to rise up to 2 years before an admission with a PCD with a peak at the time of diagnosis. This peak is consistent with previous literature (Melton et al, 2005) , suggesting that a fracture is the presenting symptom for PCD in a significant number of cases. Presenting with MM as an emergency, such as with a pathological fracture, is associated with poorer survival compared with urgent referrals from primary care (National Cancer Registration and Analysis Service 2016). The rise in fracture rate in the preceding 2 years may represent patients in whom an earlier diagnosis of symptomatic myeloma could have been made at the time of fracture, or patients who had MGUS with poor bone health. A further prospective study screening for a PCD in patients with fractures is needed to determine the true incidence and nature of PCD in patients with fractures.
There is an increased risk of PCD after an admission with a fracture, which was still seen at 2 years post-fracture. The risk of PCD was significantly higher in patients with more than one fracture within 5 years. Fractures are often caused by substantial trauma, and an underlying vulnerability to fracture may not be sought. However, fractures in patients with MGUS and MM are more likely to be associated with mild or moderate trauma (Melton et al, 2004 (Melton et al, , 2005 . This highlights the importance of investigating for a PCD, especially in patients with an innocuous mechanism of injury and in those presenting with repeated fractures.
There are limitations associated with HES data to study the incidence of PCD. In this study, the date of the first admission that included a coded diagnosis of PCD was taken as a surrogate for date of diagnosis. Patients who have been referred with a PCD and are managed as outpatients will not be included in the data. We acknowledge that our data represents a specific cohort of in-patient activity and should be interpreted in this context. However, our approach has been used previously (Evison et al, 2016) , and it is unlikely that an outpatient diagnosis of PCD would be missed on the patient's first subsequent admission to hospital. Limitations to HES have been recognised in other contexts, including acute myocardial infarction and stroke (Herrett et al, 2013; Barer & Cassidy, 2014) . Nevertheless, the accuracy of diagnosis codes has been evaluated at over 95% (Burns et al, 2012) , and the overall age-standardised rate (ASR) of PCD in this study (ASR 10Á9 in men and 8Á5 in women in 2013) is similar to the most recent UK data provided by the National Institute for Health and Care Excellence (ASR 12Á4 in men and 7Á6 in women in 2013) (National Cancer Registration and Analysis Service, 2016). Fractures that do not require admission, such as those treated solely in emergency and outpatient departments, will be missed from this analysis. Fractures associated with a hospital admission are likely to reflect a significant burden of disease and are therefore a relevant subset of fractures to investigate. This approach also circumvents the significant heterogeneity of data quality seen in HES emergency department data. In HES data, a fracture may be recorded using multiple codes in a single admission and consequently it was not possible to reliably differentiate between traumatic, osteoporotic and pathological fractures.
In conclusion this study confirms a high risk of fractures for patients with a PCD despite prophylaxis with bisphosphonates. There is an association between both prior and new fracture and poorer overall survival with PCD, and an increase in fractures is seen in the 2 years before admission with a PCD. The observational design and limited detail contained within the data prevent further conclusions being reached. More focussed work is needed to investigate further the correlation between fractures, timing of diagnosis and clinical outcomes in patients with myeloma and MGUS.
